Get the Stockscreener App
0.329
8.28%
-0.0297
Pre-market:
.31
-0.019
-5.78%
Leap Therapeutics Inc stock is traded at $0.329, with a volume of 7.27M.
It is down -8.28% in the last 24 hours and up +12.90% over the past month.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
See More
Previous Close:
$0.3587
Open:
$0.3274
24h Volume:
7.27M
Relative Volume:
5.58
Market Cap:
$13.63M
Revenue:
$1.50M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.197
EPS:
-1.67
Net Cash Flow:
$-55.17M
1W Performance:
-1.50%
1M Performance:
+12.90%
6M Performance:
-35.48%
1Y Performance:
-84.18%
1-Day Range:
$0.302
$0.3399
1-Week Range:
$0.2848
$0.37
52-Week Range:
$0.2223
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.329 | 14.86M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
674.90 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-29-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
How to recover losses in Leap Therapeutics Inc. stockMachine Learning Intraday Signal Forecast - Newser
Real time alert setup for Leap Therapeutics Inc. performanceFree Daily Volume Spike Trading Signals - Newser
Analyzing Leap Therapeutics Inc. with multi timeframe chartsFree AI-Powered Trade Planning with Indicators - Newser
Leap Therapeutics (LPTX.O) Sees Sharp Intraday Drop: What's Behind the Move? - AInvest
Will earnings trigger a reversal in Leap Therapeutics Inc.Free AI Driven Stock Trend Forecast - Newser
What data driven models say about Leap Therapeutics Inc.’s futureWeekly Portfolio Update with ROI Focus - Newser
What’s next for Leap Therapeutics Inc. stock priceChart Driven Opportunity Scanner with Alerts - Newser
Why is Leap Therapeutics Inc. stock attracting strong analyst attentionFree Stock Index Interpretation - Jammu Links News
What is the dividend policy of Leap Therapeutics Inc. stockMaximize returns with strategic portfolio planning - Jammu Links News
Is Leap Therapeutics Inc. a growth stock or a value stockTrack top-performing stocks effortlessly - Jammu Links News
Is Leap Therapeutics Inc. a good long term investmentAmplify your gains with low-risk picks - Jammu Links News
Should I hold or sell Leap Therapeutics Inc. stock in 2025Discover stocks with explosive potential - Jammu Links News
What makes Leap Therapeutics Inc. stock price move sharplyOutstanding capital growth - Jammu Links News
What are Leap Therapeutics Inc. company’s key revenue driversPhenomenal capital gains - Jammu Links News
What is Leap Therapeutics Inc. company’s growth strategyMaximize gains with data-driven trading alerts - Jammu Links News
What are the latest earnings results for Leap Therapeutics Inc.Invest confidently with data-driven strategies - Jammu Links News
Predicting Leap Therapeutics Inc. trend using moving averagesFree Growth Based Stock Signal Screener - newser.com
How does Leap Therapeutics Inc. compare to its industry peersExpert guidance for superior capital growth - Jammu Links News
When is Leap Therapeutics Inc. stock expected to show significant growthDiscover dynamic stocks ready to soar - Jammu Links News
How volatile is Leap Therapeutics Inc. stock compared to the marketBuild a diversified portfolio for steady growth - Jammu Links News
What catalysts could drive Leap Therapeutics Inc. stock higher in 2025Powerful market insights - Jammu Links News
How Leap Therapeutics Inc. stock performs during market volatilityAI Pattern Recognition and Trade Prediction - newser.com
How to integrate Leap Therapeutics Inc. into portfolio analysis toolsDay Trading Plan with Entry Risk Management - Newser
Momentum divergence signals in Leap Therapeutics Inc. chartAlgorithmic Prediction of Market Breakouts - Newser
Using data filters to optimize entry into Leap Therapeutics Inc.Weekly Market Direction and Sector Summary - Newser
Layoff Tracker: Moderna Cutting 10% of Workforce Globally - BioSpace
Leap Therapeutics Completes Promising Phase 2 Cancer Study, Enhancing Oncology Market Prospects - AInvest
Combining price and volume data for Leap Therapeutics Inc.Smart Chart Forecasting with AI Algorithms - Newser
Is Leap Therapeutics Inc. stock reversal real or fakeAlgorithmic Prediction of Market Breakouts - Newser
Does Leap Therapeutics Inc. qualify in momentum factor screeningBear Market Safe Zone Technical Analysis - Newser
Is Leap Therapeutics Inc. a candidate for recovery playMarket Ready Picks with Technical Support - Newser
Will Leap Therapeutics Inc. stock recover after recent dropReal-Time Entry Forecast with Accuracy Metrics - Newser
Why Leap Therapeutics Inc. stock attracts strong analyst attentionShort-Term Sector Movement Forecast Generator - Newser
Analyzing drawdowns of Leap Therapeutics Inc. with statistical toolsFree Low Risk Buy Zone Opportunity Watch - Newser
Published on: 2025-07-30 05:02:13 - metal.it
Leap Therapeutics Inc.’s Price Action Aligns with Quant SignalsReal Trader Watchlist of Hot Stocks Released - metal.it
When is the best time to exit Leap Therapeutics Inc.Long-Term Signal Tracking and Profit Summary - Newser
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):